Loading stock data…
CTMX
$4.18-0.04 (-0.95%)
Market ClosedLast close May 1
CytomX Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CytomX Therapeutics, Inc. in the Healthcare sector is trading at $4.18. The stock is currently 49% below its 52-week high of $8.21, remaining 8.9% above its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why CTMX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.18
Potential Upside
5%
Whystock Fair Value$4.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$13.67+227.0%
Range$11.00 – $17.00
Fundamentals
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology bio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$996.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.54%
Volume
Today's trading volume
2.89M
Recent News
Small Cap or Megacap: Which Healthcare Stock Is Right for You?
Healthcare companies with different market caps offer different rewards and challenges.
CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress
CytomX Therapeutics (NASDAQ:CTMX) is one of the best healthcare penny stocks to buy according to hedge funds. On March 24, analysts at Jefferies reiterated their Buy rating on CytomX Therapeutics (NASDAQ:CTMX) and set a $16 price target. The research firm remains bullish on the company following topline results from its candidate drug, Varseta-M. Varseta-M is […]
Analysts Bullish on CytomX Therapeutics (CTMX) As CTMX Prices $250 Million Offering
CytomX Therapeutics, Inc. (NASDAQ:CTMX) earns a spot on our list of the best penny stocks set to explode. As of April 8, 2026, all covering analysts rate CytomX Therapeutics, Inc. (NASDAQ:CTMX) as a “Buy,” with the consensus price target of $12 indicating a 179.07% upside. In addition to pre-funded warrants for 1,179,245 shares issued to […]
How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data
The fair value estimate for CytomX Therapeutics has shifted slightly to US$13.67 from US$13.44, signaling a modest recalibration in how the story is being modeled. This tweak lines up with fresh Street research, where multiple firms have raised price targets and at least one major bank has moved to a more positive rating after reviewing new Phase 1 expansion data in late line colorectal cancer. As you read on, you will see how to track these changing views and what they might mean for your...
CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the best multibagger penny stocks to invest in. On March 23, analysts at Piper Sandler reiterated an Overweight rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) and increased the price target to $12 from $10. The price target hike comes against the backdrop of topline Phase 1 data on varsetatug […]